01 June 2015

BPC-M-10-2015_rev1

Draft minutes of the 10th meeting of the Biocidal Products Committee (BPC)

14 - 16 April 2015

Part I - Summary Record of the Proceedings

1. Welcome and apologies

The Chairman of the Biocidal Products Committee (BPC) welcomed the participants to the tenth BPC meeting.

The Chairman welcomed on the occasion of the tenth BPC meeting, ECHA's Executive Director, Mr Geert Dancet to give the welcome address.

The Chair mentioned some changes in the BPC membership, namely the appointment of the new French member and alternate member, Ms Aurélie Chezeau and Ms Romy Collet respectively; the appointment of Ms Teresa Borges as the new Portuguese member; the change of roles of the Latvian member and alternate, with Ms Julija Brovkina being now the member and Ms Anta Jantone the alternate member.

The Chair noted the re-organisation of the BPC Secretariat team in which Judit Janossy is now responsible for the scientific matters and Ligia Negulici for all administrative matters.

The Chair informed the BPC members of the participation of 22 members including five alternates and one invited expert, exceptionally replacing the Swedish member for this meeting.

Nine advisers, one representative of the European Commission and three representatives from accredited stakeholder organisations (ASOs) were present at the meeting. Apologies were received from five members and one ASO (AISE).

Applicants were present for their specific substances and the details are provided in the summary record of the discussion for the substances and Part III of the minutes.

The Chairman then gave the floor to Mr Dancet for his welcome address to BPC.

2. Agreement of the agenda

The Chair introduced the final draft agenda (BPC-A-10-2015_rev1), tabled as a room document, and invited any additional items.

An additional item concerning the working procedure in the BPC Working Groups was added to the agenda under Item 8, following a proposal from a member. Another point regarding the publication of the list of new active substance applications was included under Item 6.2.

The agenda was adopted with the proposed changes. The final version of the agenda was to be uploaded to the BPC CIRCABC IG as part of the meeting minutes.

The Chair informed meeting participants that the meeting would be recorded for the purpose of the minutes and that the recording would be destroyed after the agreement of the minutes.

The list of meeting documents and the final version of the agenda are included in Part IV of the minutes.

3. Declarations of potential conflicts of interest to the agenda

The Chair invited BPC members, alternates and advisers to declare any potential conflicts of interest in relation to the agreed agenda. None were declared.

4. Agreement of the draft minutes and review of actions arising from BPC-9

The revised draft minutes from BPC-9 (BPC-M-9-2015) incorporating the comments received from members, were agreed.

The Chair updated the members on the status of the actions arising from BPC-9. As concerns the overview table on harmonised classification and labelling and PBT evaluation for biocides, the members were informed that an updated table has been uploaded to CIRCABC including also the schedule of the RAC meetings for the remainder of the year.

Further, the Chair reported that the working procedure was updated in light of the discussions at previous meeting and that the revised version was uploaded to CIRCABC and published on the ECHA website. The document indicating the timelines for the process flows was to be shortly published as well.

Actions:

SECR: To upload the agreed minutes to the BPC CIRCABC IG and to the ECHA website after the meeting;

5. Administrative issues

5.1 Housekeeping issues

The SECR highlighted the key aspects of the housekeeping rules including the safety and security rules.

5.2 Report from other ECHA bodies

The Chair introduced document BPC-10-2015-01 covering the report from the other ECHA Committees and provided to members for information purposes. He pointed out the adoption of several opinions for harmonised classification and labelling, which could be of interest to the BPC.

6. Work Programme for BPC for 2015– 2016

6.1 Revised Work Programme 2015-2016

6.2 Outlook

Agenda items 6.1 and 6.2 were discussed together. The Chair introduced the BPC Work Programme for 2015-2016, mentioning that for 2015 56 opinions are scheduled of which 38 are from the "back-log"; 12 opinions are for active substance PT combinations from the first priority list of the Review Regulation 1062/2014 and 12 from the second priority list. The Chair asked the BPC members to give priority to the first and second priority lists active substance PT combinations, noting that more than half of the opinions for 2015 are related to other priority lists. About the second priority list, following a question from a member, the Chair clarified that more than 90 opinions will have to be delivered by the BPC by December 2017. Giving priority to these second list substance PT combinations now will prevent a situation where such a high number of opinions will need to be delivered in potentially a relatively short period of time in that year and avoid the need to take special measures. The SECR will analyse the situation for the second priority list in more detail per MSCA before the next BPC meeting. Consequently, the

SECR will contact individual MSCAs regarding their situation and identify if technical and/or scientific assistance may be needed to deliver their second priority list active substance PT combinations. The Commission clarified that the deadlines in the Review Regulation were set with the aim to spread the work for the BPC. In addition, the Commission recommended that ECHA prepare an overview of uses and scenarios addressed for specific PTs, which will streamline and harmonise future evaluations and prevent withdrawal of draft opinions at a late stage due to ongoing technical and scientific discussions. Several members asked the SECR to consider the future applications for Union authorisation for the work programme of the BPC.

Following a question from a member, the SECR will investigate if information on ongoing evaluations for applications for new active substance approval under the BPR can be disseminated.

Following a question from a member on the outlook, where sometimes the information "in-situ" is added, the Commission clarified that for the precursor – active substance combinations included in the Review Programme (as indicated in the document "Management of in situ generated active substances in the context of the BPR" adopted at the 59th CA meeting) the deadline of the Review Regulation apply. For the precursor – active substance combinations not included in the Review Programme the applicant has two years to submit a dossier after the notification is declared compliant by ECHA.

Actions for agenda item 6.1:

- **Members:** to send information on any further changes to the Work Programme (WP) to the SECR **by 24 April 2015**.
- **SECR:** on the basis of the changes to update the WP on the ECHA web site and in the BPC CIRCABC IG.
- **SECR:** to investigate the possibility to disseminate new active substance applications on ECHA's website and/or BPC CIRCABC IG.

Actions for agenda item 6.2:

- **Members:** to check the information in the tables for their active substance/PT combinations and inform the SECR of any corrections.
- **Members:** to inform the SECR when their evaluations will be submitted for their active substance/PT combinations listed in the annexes to the document 'Outlook 2015-2016' **by 30 April 2015.**
- **Members:** to contact the SECR if technical or scientific support is needed to submit the draft CAR by the legal deadline.
- **SECR:** to include the information provided, schedule the substance/PT combinations in the work programme and present an update at BPC-11.

7. Applications for approval of active substances

7.1 Working procedure and templates: update from SECR

7.1a Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval

The Chair introduced the document (BPC-10-2015-04) mentioning that some changes were made based on the discussions in the previous meeting. Also, there was an editorial change introduced related to the condition on the use of personal protective equipment which will also apply for the relevant PT21 condition.

Actions:

- **Members:** to apply the standard phrases in future draft opinions.
- **SECR:** to check where in the Assessment Report template additional information requirements (like requirements for further data on efficacy) on the representative product can be added.
- **SECR:** to revise and upload the catalogue to the BPC CIRCABC IG after the meeting.

7.2 Draft BPC opinion on C(M)IT/MIT for PT 2, 4, 12 and 13

The Chair welcomed the applicants for this item. The Chair noted that the applicants had not objected to the presence of ASOs during the discussion. The session was therefore kept open.

The AR for CMIT/MIT PT 2, 4, 12 and PT 13 were agreed by the BPC, subject to the changes agreed on the general issues related to the AR of C(MIT)/MIT during BPC-9.

Related to the oilfield injection scenario for PT 12 the potential for exposure of workers was discussed. The potential for worker exposure is the highest during recycling of the mud in open systems, handling of the recycled mud or use of mud for injection, especially mud cleaning. A member clarified that drilling is a combination of recycling mud from the drilling and enhanced oil production. Based on this explanation, the phrase "oilfield injection mud" was replaced by "drilling". It was acknowledged that there is limited experience for the environmental exposure assessment and the current models used to estimate exposure may need to be improved. It was stated that relevant information may be submitted for product authorisation that could lead to further refinements in the environmental risk, e.g. the degradation of the active substance in the mud, treated water etc.

A member stated that CMIT/MIT for PT 13 should be considered as a candidate for substitution based on its potent sensitising properties. Another member supported this proposal. The eCA explained that this critical effect can be managed with very restrictive risk mitigation measures to avoid any skin contact during use of biocidal products by professionals and by limiting the concentration of C(M)IT/MIT in treated articles used by professionals and non-professional below the threshold value set for sensitizing properties, when skin contact cannot be avoided by other measures.

Regarding PT 13 the availability of treated articles (ready to use products) on the market was discussed. One member was proposing to add a condition regarding a concentration limit for treated articles and one regarding labelling requirements for treated articles as was already done for C(MIT)/MIT PT6.

Concerning labelling requirements for treated articles, the Chair referred to the on-going discussions at CA level.

Regarding PT 2 and PT 4 a member was proposing to add a condition imposing a concentration limit for treated articles. This proposal was not taken on board since the thresholds set in the CLP regulation only apply to mixtures. However, for PT 2 and PT 4 only "solid" treated articles not being mixtures, are expected. Therefore the CLP regulation is not applicable.

The BPC adopted by consensus its opinion on an application for the approval of C(MIT)/MIT in use of PT 12. The BPC adopted by majority its opinions on an application for the approval of C(MIT)/MIT for PT 2, 4 and 13. One member did not support these opinions.

Actions:

- **Rapporteur**: to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR by **28 May 2015**.
- **Member** to provide its minority opinion on the opinions for PT 2, 4 and 13 to the SECR **by 23 April 2015**.
- **SECR**: to revise the draft opinion in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur.
- **SECR**: to forward the adopted opinion to COM **by 7 May** 2015 and publish it on the ECHA website.

7.3 Draft BPC opinion on peracetic acid for PT 1, 2, 3, 4, 5 and 6

The Chairman welcomed the applicant for this item. The Chairman noted that the applicant had not objected to the presence of ASOs during the discussion. The session was therefore kept open.

The rapporteur introduced the assessment report and (AR) and opinions (OP). General issues related to the assessment report (AR) and opinions were discussed in detail.

Assessment report (PT 1, 2, 3, 4, 5, 6)

- Identity, where it was confirmed that the active substance is peracetic acid.
- Scope, where it was highlighted that the evaluation covered the use of peracetic acid in equilibrium and that the evaluation does not cover the active substances or biocidal products containing peracetic acid generated *in situ*.
- Non-equilibrium peracetic acid, where it was concluded that the risks from the non-equilibrium peracetic acid are not covered in the assessment.
- Specification, where it was agreed that a written procedure would be undertaken to allow the members of the BPC to conclude on the proposed reference specification. The written procedure will address whether or not the specification should cover both peracetic in equilibrium and non-equilibrium mixtures. If non-equilibrium peracetic acid is covered, the data requirements for product authorisation need to be clarified as well if an application for technical equivalence is necessary.
- A technical equivalence assessment may be necessary. The additional information will be provided in the AR.
- Classification, where it was agreed that rapporteur will check the classification during the process of the CLH proposal.

The AR was agreed subject to the minor modifications described in the open issues table.

The following key issues were discussed and agreed with regards the opinions (relevant for all PTs):

- The written procedure will address whether or not there is a need to include a maximum concentration limit of peracetic acid in the aqueous equilibrium solution

as part of the reference specification, where it was agreed to include in the written procedure for the specification whether there is a need to set this limit or not.

- The need to add a reference to Regulation 98/2013 on the marketing and use of explosives precursors, given the presence of hydrogen peroxide in the aqueous equilibrium solution.

The BPC will adopt the opinions on an application for the approval of these active substance PT combinations via written procedure. The opinions will be adopted by consensus pending the agreement on the reference specification, which will be part of the written procedure.

Actions:

- **Rapporteur**: to send the proposal on the specification to SECR.
- **SECR**: to launch the written procedure according to Article 20 of the Rules of Procedure of the BPC. The written procedure will contain the revised draft opinion based on the BPC-10 discussions and the proposal of the Rapporteur on the specification.
- **SECR**: to consult the WGs on the information requirement to perform technical equivalence for peracetic acid, if applicable.

7.4 Draft BPC opinion on ampholyt for 3

The Chair welcomed the applicant and their expert for this item. The Chair noted that the applicant had not objected to the presence of ASOs during the discussion. The session was therefore kept open.

The rapporteur introduced the draft opinion and assessment report, highlighting that the active substance was previously discussed at BPC-8 2014. Following the agreements at that BPC meeting, e-consultations in the Environment Working Group and Human Health Working Group took place on the refinements proposed by the applicant.

The assessment report (AR) was agreed with further details described in the open issues table.

The following elements present in the opinion were discussed in more detail:

- Human health secondary exposure (scenario of a children crawling on the floor), where it was agreed that the scenario was not relevant for the current PT 3 application.
- Endocrine disruption properties, where the rapporteur clarified that ampholyt is not to be considered as endocrine disruptor.
- Footbath scenario, where it was clarified that the risk for animals walking through footbath had not been addressed.
- New approach for deriving the predicted environmental concentration (PEC) following manure application on soil (taking accumulation in soil as well as adsorption properties into account). This new approach was considered as worst case compared to the method applied for other relevant PT 3 and PT 18 substances so far.
- Section 2.3., where a new text was proposed for the provisions in order to reflect the environmental risks identified.

The BPC adopted by consensus its opinion on an application for the approval of the active substance for PT 3.

Actions:

- **Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR by 28 May 2015.
- **SECR:** to revise the draft opinion in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur.
- **SECR:** to forward the adopted opinion to COM by 7 May and publish it on the ECHA website.
- **SECR:** to initiate a general discussions at the WG Environment on the applicability of the method used for ampholyt and its relevance for other active substances for other PTs like 3 and 18.

8. Any other business

8.1 Introduction of the Secure CIRCABC platform

The Chair introduced Piotr Sosnowski from the ECHA Committees Unit, who gave a general presentation on the Secure CIRCABC project, that will be implemented in the second part of the year. The main points highlighted during the presentation were: the scope of the project, its timelines and the main actions scheduled in the coming months.

The Chair mentioned that the folder structure of the BPC interest group would be analysed in order to identify possible ways to further simplify it.

Following a question from one member, it was clarified that this project is only limited to ECHA, therefore it concerns only those interest groups managed by ECHA. As for the archiving function, it was highlighted that the migration to the new platform does not necessarily imply a mass deletion of documents but that it is up to the interest groups leaders to decide if documents can be removed. The Chair stated that archiving is a different process, where for example retention times are relevant for different type of documents, but that indeed an interest group leader can decide to keep documents for longer periods.

One member asked whether the introduction of a search functionality and possibility to create shortcuts have been considered. The presenter informed that for the time being these aspects are not within the scope of the project but they might be considered for future developments. Another aspect to be investigated regards the batch download functionality.

Actions:

- **SECR:** to inform members on future steps concerning the migration to the new platform.
- **Members:** to forward suggestions on the structure of the BPC CIRCABC IG.

8.2 Way forward with the public consultation process

The Chair introduced document BPC-11-2015-06 and mentioned that the topic has already been on the agenda of a previous meeting. The document presents the status of the ongoing actions of improving the public consultation process. The Chair noted that the improvement also concerns the dedicated pages on the ECHA website, in terms of information provided, and the modality of data submission by interested third parties.

Members were invited to provide further comments and suggestions. The Chair also reported on the latest public consultation on two substances, concluded at the beginning of April, which yielded very limited information, similarly to previous cases.

The COM observer noted that another element which is needed to reflect upon is the way in which the information provided during the public consultation is to be taken into account by the BPC, as this is an obligation set by the BPR.

Actions:

- **SECR:** to inform members when the website changes become effective.
- **Members:** to send comments to the SECR by **15 May 2015**.

8.3 Participation of Switzerland in the BPC

The Chair introduced document BPC-11-2015-20. The Chair mentioned that requesting the agreement of the BPC to the participation of Switzerland in the work of the Committee is a formal step following the entry into force of the revised Chapter 18 (Annex I) of the Mutual Recognition Agreement (MRA) between the European Union and the Swiss Confederation and the decision of ECHA's Management Board to invite Switzerland to participate in the work of the BPC. The Swiss member will have the same rights and obligations as any other member except for the voting right (as is currently the case for Norway).

The BPC agreed to the participation of Switzerland in the work of the Committee. It was mentioned that the Rules of Procedure would be amended to reflect this change.

Actions:

SECR: to amend the BPC Rules of Procedure.

8.4 Feedback from the Workshop "Reviewing the active substance assessment process"

The Chair presented briefly the structure of the workshop held on 5 March and mentioned that a summary document, providing an overview of the workshop, has been distributed to the participants and to BPC and WG members. The Chair highlighted that many proposals received during the workshop regard the increase of efficiency and effectiveness of the active substance approval process and that some of these proposals can be implemented almost immediately while other need first further discussion. Some proposals regarded the modification of the process itself (i.e. of the various steps in the process) and some relate to the role of the Agency and especially the ECHA Dossier Manager in the process.

The Chair informed that a document will be prepared for discussion for either BPC-11 or BPC-12 on the steps undertaken in light of the discussions and proposals at the workshop.

One member was of the opinion that the BPC and other actors involved in the process should question whether the target for approval of active substances (in terms of the deadlines set) is achievable. The role of the working groups and of their chairs was also brought to attention, with a suggestion from one member that they should try to avoid those technical discussions which are not really relevant for the decision making.

The COM observer pointed out that a re-focus on hazard assessment during the process might be beneficial although it was noted by some members that this might lead to postponement of problems to the product authorisation stage. Some topics like too conservative Emission Scenario Documents (ESDs) might even be identified too late if they were not discussed during the active substance approval process.

At a general level it appeared clear that a more balanced approach between the "scientific ambition" and other objectives (for example the fact that the active substance approval assessment pave the way for the methodology to be followed under product authorisation) has to be identified, in order to be able to meet the 2024 deadline.

A discussion took place on how the BPC will manage to handle applications for Union authorisation in addition to the workload of the review programme.

Actions:

SECR: to report on the status of the follow up at the BPC.

8.5 Working procedure in the Efficacy Working Group

One member referred to the last discussion in the Efficacy Working Group where apparently a vote was taken on an issue for which no consensus could be reached. The member, supported by several other members, objected to the fact that only core members were allowed to vote and stated that voting is not an appropriate procedure for technical and scientific discussions taking place in the Working Groups. The Chair stated that indeed since agreement could not be reached during the discussion at the Working Group, the Chair decided to ask all members to express their opinion. The Chair clarified that the intention was not to initiate a formal voting procedure, like the procedure described in the Rules of Procedure for the BPC, but to ask the members to express their opinion in order to seek the majority view of the meeting. The Chair informed that after internal consultation the SECR does agree that this shall not be limited to core members but that also the opinion of flexible members of the WGs have to be taken into account. It was further discussed how to proceed in case there is no majority after seeking the opinions from the core and flexible members. Instead of considering then only the opinions of the core members, it was preferred to refer the issue than to the BPC. It was decided that the SECR will further reflect on how to proceed in these situations and come back on it at the next BPC meeting.

Actions:

SECR: to propose a way forward how to proceed when the WG cannot reach consensus at the BPC.

9. Agreement of the action points and conclusions

Part II contains the main conclusions and action points which were agreed at the meeting.

Part II - Main conclusions and action points

Agreed at the 10th meeting of BPC

14-16 April 2015

Agenda point	
Conclusions / decisions / minority positions	**Action requested after the meeting (by whom/by when)**
Item 2 - Agreement of the agenda	
The final draft agenda was agreed without further changes.	**SECR:** to upload the agreed final agenda to the BPC CIRCABC IG as part of the draft meeting minutes after the meeting.
Item 4 - Agreement of the minutes and review of actions from BPC-9	
The revised version of the minutes of BPC-9 was agreed as proposed subject to several editorial modifications.	**SECR:** to upload the agreed minutes to the BPC CIRCABC IG and to the ECHA website after the meeting.
Item 6 - Work programme for BPC	
6.1 Revised Work Programme 2015-2016	
	Members: to send information on any further changes to the Work Programme (WP) to the SECR **by 24 April 2015**. **SECR:** on the basis of the changes to update the WP on the ECHA web site and in the BPC CIRCABC IG. **SECR:** to investigate the possibility to disseminate new active substance applications on ECHA's website and/or BPC CIRCABC IG.
6.2 Outlook	
Priority shall be given to the first and second priority list substances of the Review Programme Regulation. Also for the second priority list this shall be the case to prevent a peak of submissions to ECHA by the deadline stated in this Regulation.	**Members**: to check the information in the tables for their active substance/PT combinations and inform the SECR of any corrections. **Members**: to inform the SECR when their evaluations will be submitted for their active substance/PT combinations listed in the annexes to the document 'Outlook 2015-2016' **by 30 April 2015**. **Members**: to contact the SECR if technical or scientific support is needed to submit the draft CAR by the legal deadline. **SECR:** to include the information provided, schedule the substance/PT combinations in the work programme and present an update at BPC-11.

Item 7 - Applications for approval of active substances	
7.1 Working procedure and templates: update from SECR	
7.1a Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval	
	Members: to apply the standard phrases in future draft opinions. **SECR:** to check where in the Assessment Report template additional information requirements (like requirements for further data on efficacy) on the representative product can be added. **SECR:** to revise and upload the catalogue to the BPC CIRCABC IG after the meeting.
7.2 Draft BPC opinion on C(M)IT/MIT for PT 2, 4, 12 and 13	
The BPC adopted by consensus its opinion on an application for the approval of the active substance for PT 12. The BPC adopted by majority its opinions on an application for the approval of the active substance for PT 2, 4 and 13. One member did not support the opinions.	**Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR **by 28 May 2015.** **Member** to provide its minority opinion on the opinions for PT 2, 4 and 13 to the SECR by **23 April 2015**. **SECR:** to revise the draft opinion in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur. **SECR:** to forward the adopted opinion to COM **by 7 May** and publish it on the ECHA website.
7.3 Draft BPC opinion on peracetic acid for PT 1, 2, 3, 4, 5 and 6	
No conclusion could be reached on the specification. All other elements of the opinion were agreed. The BPC will adopt the opinions on an application for the approval of these active substance PT combinations via written procedure. The opinions will be adopted by consensus pending the agreement on the reference specification, which will be part of the written procedure.	**Rapporteur:** to send the proposal on the specification to **SECR.** **SECR:** to launch the written procedure according to Article 20 of the Rules of Procedure of the BPC. The written procedure will contain the revised draft opinion based on the BPC-10 discussions and the proposal of the Rapporteur on the specification. **SECR:** to consult the WGs on the information requirement to perform technical equivalence for peracetic acid, if applicable.
7.4 Draft BPC opinion on ampholyt for PT 3	
The BPC adopted by consensus its opinion on an application for the approval of the active substance for PT 3.	**Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR **by 28 May 2015.** **SECR:** to revise the draft opinion in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur. **SECR:** to forward the adopted opinion to COM **by 7 May** and publish it on the ECHA website. **SECR**: to initiate discussions at the WG

	Environment on the applicability of the method used for ampholyt for other PTs like 3 and 18.
Item 8 Any other business	
8.1 Introduction of the Secure CIRCABC platform	
	SECR: to inform members on future steps concerning the migration to the new platform. **Members:** to forward suggestions on the structure of the BPC CIRCABC IG.
8.2 Way forward with the public consultation process	
	SECR: to inform members when the website changes become effective. **Members:** to send comments to the SECR by **15 May 2015**.
8.3 Participation of Switzerland in the BPC	
The BPC agreed to the participation of Switzerland in the BPC.	**SECR:** to amend the BPC Rules of Procedure.
8.4 Feedback from the Workshop "Reviewing the active substance assessment process"	
	SECR: to report on the status of the follow up at the BPC.
8.5 Other items	**SECR**: to propose a way forward how to proceed when the WG cannot reach consensus at the BPC.

Part III - List of Attendees

Members	Advisers
BROVKINA Julija (LV)	COISSARD Vincent (FR)
CHEZEAU Aurélie (FR)	HYVÄRINEN Tuija (FI)
COSTIGAN Michael (UK)	HÄMÄLÄINEN Anna-Maija (FI)
DONS Christian (NO)	KARHI Kimmo (FI)
DRAGOIU Mihaela-Simona (RO)	KOMEN Corine (NL)
GONZÁLEZ MÁRQUEZ María Luisa (ES)	LÖFBOM Johanna (SE)
HADJIGEORGIOU Andreas (CY)	PENTTINEN Sari (FI)
HARRISON John (IE)	PLATTNER Edmund (AT)
JÄGER Stefanie (DE)	WEINHEIMER Viola (DE)
LARSEN Jørgen (DK)	
MERISTE Anu (EE)	**Accredited Stakeholder Organisations**
MIKOLASKOVA Denisa (SK)	BRUYNDONCKX Raf (Cefic)
NELEMANS Maartje (NL)	LEROY Didier (CEPE)
RUBBIANI Maristella (IT)	REID Kirsty (Eurogroup for Animals)
SPATNY Nina (AT)	
TERNIFI Vesna (SL)	**ECHA Staff**
TUUSA Tiina (FI)	JANOSSY Judit
	NEGULICI Ligia
Alternate members	RODRIGUEZ UNAMUNO Virginia
AZDAD Karima (BE)	VAN DE PLASSCHE Erik
CHROBAK Robert (PL)	
MIKOLÁS Jan (CZ)	
SZÁSZ Attila (HU)	
TURK Rajka (HR)	
Invited expert	
HAHLBECK Edda (SE)	
European Commission	
CHATELIN Ludovic (DG SANTE)	

Applicants	
BERENDS Albert (Solvay) for peracetic acid PTs 1-6	
LEONHARDT Wolfgang (Evonik) for ampholyt PT 2, 3 and 4	
QUÉROU Rodolphe (DOW) for C(M)IT/MIT PT 2, 4, 12 and 13	
SCHOESTER Monika (Thor GmbH) for C(M)IT/MIT PT 12 and 13	
Experts accompanying applicants	
ESCHRICH Dietmar (accompanying LEONHARDT Wolfgang) for ampholyt PT 2, 3 and 4	
HINDLE Stuart (accompanying QUÉROU Rodolphe) for C(M)IT/MIT PT 2, 4, 12 and 13	
WALTER Bernd (accompanying SCHOESTER Monika) for C(M)IT/MIT PT 12 and 13	
WERNER Michael (accompanying BERENDS Albert) for peracetic acid PTs 1-6	
Apologies	
BUSUTTIL Ingrid (MT)	
BORGES Teresa (PT)	
CAZELLE Elodie (AISE)	
MAJUS Saulius (LT)	
TERNIFI Vesna (SI)	
ZIGRAND Jeff (LU)	

Part IV - List of Annexes

Annex I List of documents submitted to the members of the Biocidal Products Committee

Annex II Final agenda

Annex I

Documents submitted to the members of the Biocidal Products Committee for the BPC-9 meeting

Meeting documents			
Agenda Point	**Number**	**Title**	
2	BPC-A-10-2015	Draft agenda	
4	BPC-M-9-2015	Draft minutes from BPC-9	
5.2	BPC-10-2015-01	Administrative issues and report from the other Committees	
6.1	BPC-10-2015-02	BPC updated Work Programme 2015-2016	
6.2	BPC-10-2015-03	Outlook	
7.1a	BPC-10-2015-04	Catalogue of specific conditions and elements at the PA stage	
8.1	BPC-10-2015-05	Introduction of the Secure CIRCABC platform	
8.2	BPC-10-2015-06	Way forward with the public consultation process	
8.3	BPC-10-2015-20	Participation of Switzerland in the BPC	
Substance documents			
Agenda Point	**Number**	**Substance-PT**	**Title**
7.2	BPC-10-2015-07A	C(M)IT/MIT PT 2	Draft opinion
	BPC-10-2015-07B		Assessment report
	BPC-10-2015-07C		Open issues
7.2	BPC-10-2015-08A	C(M)IT/MIT PT 4	Draft opinion
	BPC-10-2015-08B		Assessment report
	BPC-10-2015-07C		Open issues
7.2	BPC-10-2015-09A	C(M)IT/MIT PT 12	Draft opinion
	BPC-10-2015-09B		Assessment report
	BPC-10-2015-07C		Open issues
7.2	BPC-10-2015-10A	C(M)IT/MIT PT 13	Draft opinion
	BPC-10-2015-10B		Assessment report
	BPC-10-2015-07C		Open issues

7.3	BPC-10-2015-11A	Peracetic acid PT 1	Draft opinion
	BPC-10-2015-11B		Assessment report
	BPC-10-2015-11C		Open issues
7.3	BPC-10-2015-12A	Peracetic acid PT 2	Draft opinion
	BPC-10-2015-11B		Assessment report
	BPC-10-2015-11C		Open issues
7.3	BPC-10-2015-13A	Peracetic acid PT 3	Draft opinion
	BPC-10-2015-11B		Assessment report
	BPC-10-2015-11C		Open issues
7.3	BPC-10-2015-14A	Peracetic acid PT 4	Draft opinion
	BPC-10-2015-11B		Assessment report
	BPC-10-2015-11C		Open issues
7.3	BPC-10-2015-15A	Peracetic acid PT 5	Draft opinion
	BPC-10-2015-11B		Assessment report
	BPC-10-2015-11C		Open issues
7.3	BPC-10-2015-16A	Peracetic acid PT 6	Draft opinion
	BPC-10-2015-11B		Assessment report
	BPC-10-2015-11C		Open issues
7.4	BPC-10-2015-17A	Ampholyt PT 2	Draft opinion
	BPC-10-2015-17B		Assessment report
	BPC-10-2015-17C		Open issues
7.5	BPC-10-2015-18A	Ampholyt PT 3	Draft opinion
	BPC-10-2015-18B		Assessment report
	BPC-10-2015-17C		Open issues
7.5	BPC-10-2015-19A	Ampholyt PT 4	Draft opinion
	BPC-10-2015-19B		Assessment report
	BPC-10-2015-17C		Open issues

08 April 2015
BPC-A-10-2015_rev2

Draft final agenda
10th meeting of the Biocidal Products Committee (BPC)
14-16 April 2015
ECHA Conference Centre, Annankatu 18, Helsinki
14 April: starts at 10:00
16 April: ends at 13:00

Item 1 – Welcome and apologies

- **Welcome address by ECHA's Executive Director, Mr Geert Dancet**

Item 2 – Agreement of the agenda

BPC-A-10-2015_rev1

For agreement

Item 3 – Declarations of potential conflicts of interest to agenda items

Item 4 – Agreement of the minutes and review of actions from BPC-9

BPC-M-9-2014

For agreement

Item 5 – Administrative issues

5.1 Housekeeping issues

For information

5.2 Report from other ECHA bodies

BPC-10-2015-01

For information

Item 6 – Work programme for BPC

6.1 Revised BPC Work Programme 2015-2016

BPC-10-2015-02

For information

6.2 Outlook

BPC-10-2015-03

For discussion

Item 7 – Applications for approval of active substances[1]

7.1 Working procedure and templates: update from SECR

a) Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval

BPC-10-2015-04

For information

7.2 Draft BPC opinion on C(M)IT/MIT for PT 2, 4, 12 and 13

Previous discussion(s): WG II-2014, WG V-2014 and BPC-9

PT 2: BPC-10-2015-07A,B,C
PT 4: BPC-10-2015-08A,B and BPC-10-2015-07C
PT 12: BPC-10-2015-09A,B and BPC-10-2015-07C
PT 13: BPC-10-2015-10A,B and BPC-10-2015-07C

For adoption

7.3 Draft BPC opinion on peracetic acid for PT 1, 2, 3, 4, 5 and 6[2]

Previous discussion(s): TM IV-2-13, WG V-2014

PT 1: BPC-10-2015-11A,B,C
PT 2: BPC-10-2015-12A; BPC-10-2015-11B,C
PT 3: BPC-10-2015-13A; BPC-10-2015-11B,C
PT 4: BPC-10-2015-14A; BPC-10-2015-11B,C
PT 5: BPC-10-2015-15A; BPC-10-2015-11B,C
PT 6: BPC-10-2015-16A; BPC-10-2015-11B,C

For adoption

7.4 Draft BPC opinion on ampholyt for PT 3

Previous discussion(s): WG III-2014 and BPC-8

PT 3: BPC-10-2015-18A,B,C

For adoption

---

[1] For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (may cover more than one PT) and a document containing open issues (covering all the PTs to be discussed for that substance).

[2] The assessment reports and draft opinions for in-situ generated peracetic acid for PT 2, 3 and 4 will be discussed at a later BPC meeting.

Item 8 – Any other business

8.1 Introduction of the Secure CIRCABC platform

BPC-10-2015-05

For information

8.2 Way forward with the public consultation process

BPC-10-2015-06

For discussion

8.3 Participation of Switzerland in the BPC

BPC-10-2015-07

For agreement

8.4 Feedback from the Workshop "Reviewing the active substance assessment process"

For information

8.5 Working procedure in the Efficacy Working Group

For discussion

Item 9 – Agreement of the action points and conclusions

For agreement

Provisional timeline for the

10th meeting of the Biocidal Products Committee (BPC)

ECHA Conference Centre, Annankatu 18, Helsinki

14 April 2015: starts at 10:00
16 April 2015: ends at 13:00

Please note that the timings indicated below are provisional and subject to possible change. They are distributed to participants on a preliminary basis. Morning sessions usually start at 09:00.

Tuesday 14 April: morning session

Items 1-5	Opening items and administrative issues
Item 6	Work programme of the BPC 2015-16
Item 7	Applications for approval of active substances
Item 7.1	Working procedures and templates
Item 7.2	Draft BPC opinion on C(M)IT/MIT for PT 2, 4, 12, 13

Tuesday 14 April: afternoon session

Item 7.2(cont'd)	Draft BPC opinion on C(M)IT/MIT for PT 2, 4, 12, 13
Item 7.3	Draft BPC opinion on peracetic acid for PT 1, 2, 3, 4, 5, 6

Wednesday 15 April: morning session

Item 7	Follow up to previous discussions on draft substance opinions
Item 7.3(cont'd)	Draft BPC opinion on peracetic acid for PT 1, 2, 3, 4, 5, 6

Wednesday 15 April: afternoon session

Item 7.3(cont'd)	Draft BPC opinion on peracetic acid for PT 1, 2, 3, 4, 5, 6
Item 7.4	Draft BPC opinion on ampholyt for PT 3

Thursday 16 April: morning session

Item 7	Follow up to previous discussions on draft substance opinions
Item 8	Any other business
Item 8.1	Introduction of the Secure CIRCABC platform
Item 8.2	Way forward with the public consultation process
Item 8.3	Participation of Switzerland in the BPC
Item 8.4	Feedback from the Workshop "Reviewing the active substance assessment process"
Item 8.5	Working procedure in the Efficacy Working Group
Item 9	Agreement of the action points and conclusions

End of meeting

o0o